Black Box 'Best Case' Hopes On Vaginal Estradiol Dashed For TherapeuticsMD
Executive Summary
Echoing complaints of other recent complete response recipients, TherapeuticsMD charges that US FDA's request for 12-month safety data for the dyspareunia therapy TX004HR is not consistent with earlier communications with agency.
You may also be interested in...
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Immuno-Oncology Racks Up More Approvals; Bar Still Too High For Advair Generics
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: US FDA Shoots Down Lilly's Baricitinib, Approves Neurocrine's Ingrezza
The latest drug development news and highlights from our FDA Performance Tracker.